Custom cell line generation pricing varies based on the number of alleles that need to be modified and the level of challenge associated with working with the target cell line.

Horizon has divided cell line generation projects into three tiers as follows:

Tier 3 lines represent cell line generation projects that can often only be achieved through rAAV GENESIS™ gene-editing.

Custom cell line development pricing varies depending on specific project needs.  Please contact us to discuss your requirements.  Prices range from:

Completed custom cell line projects come with a one-year non-exclusive license starting from the date of delivery of the cell line. Annual renewals will apply.

Exclusivity and perpetuity options are available. Please contact us for more information.

rAAV GENESIS™ is capable of performing a wide array of genomic alterations which can be used to help you generate the disease model that you need for your experiments. These include:

Enlarge Image

Our team of scientists works collaboratively with customers from the start to finish of all projects, thus ensuring the best chance of success for any given project. We help our customers specify their projects including aiding them in choosing the most suitable parental cell lines and the design of the targeting strategy that will lead to the development of a tool and/or reagent that will add value to their research programs.

See an example of what you can expect at the completion of a project [PDF]  

Horizon has successfully executed several hundred cell line generation projects to date with more being completed all the time.

Below are just a few specific project examples:

• Knock-in EGFR (T790M) resistance mutation in RKO and MCF10a cell lines
• Knock-in IDH1 and IDH2 mutations in HCT116, MCF10a and MO59
• EML4-ALK translocation in lung and colorectal derived cell lines
• Creation of NanoLuc™ protein reporter lines
• Constitutive knock-out (exon deletions, promoter traps) in DLD1 and HCT116
• HaloTag™ protein reporter lines used for imaging and pulldown assays
• Knock-in epitope tag in MCF10a and KMS11 cells
• Knock-in shRNA resistance sequence in a range of cell lines e.g. MCF10a, RKO, LS513
• 10kb genomic deletion for use in diagnostic reagents
• KRAS (G12) mutations in SW48 and NCI-H838 cell lines
• Homozygous stop codon knock-in in breast and colorectal cells
• Conditional knock-out (+cKO/-) in colorectal cells
• Creation of knock-in panels of mutations including KRAS, EGFR and BRAF
• Exon flox on key gene in fibrosarcoma HT1080 cells
• Knock-in of PIK3CA mutations in cell lines such as MCF10A, LIM1215, Vaco, WiDr and RKO